Last reviewed · How we verify
NCT07013916: FLOURISH
Fructose is a Metabolic and Inflammatory Pathogenic Factor in Metabolic Dysfunction-associated Steatohepatitis (MASH)
NA trial testing fructose in MASH - Metabolic Dysfunction-Associated Steatohepatitis in 72 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Queen Mary University of London |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 72 |
| Start date | 30 June 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
Conditions studied
- MASH - Metabolic Dysfunction-Associated Steatohepatitis — all drugs for MASH - Metabolic Dysfunction-Associated Steatohepatitis →
- MASH With Fibrosis — all drugs for MASH With Fibrosis →
- Steatosis of Liver — all drugs for Steatosis of Liver →
Sponsor
Queen Mary University of London
Who can join
Adults 45 to 65, any sex, with MASH - Metabolic Dysfunction-Associated Steatohepatitis or MASH With Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MASLD (Metabolic dysfunction-associated steatotic liver disease) is a condition where fat builds up in the liver. It is the most common cause of liver disease worldwide. In some people, the fat can irritate the liver (inflammation) and cause damage. This is a more serious condition called MASH (Metabolic dysfunction-associated steatohepatitis). People with MASH more at risk of liver cirrhosis (advanced scarring in the liver) and liver cancer. It is not fully understood why MASLD becomes MASH, or why this happens in some people but not in others. However, it is known that our diet plays a role. Research shows a diet high in a type of sugar called fructose might make MASLD worse. Fructose is found in fruit, honey and table sugar, and lots of processed food and drinks. The body deals with fructose differently to other sugars, which is why fructose may be a problem. Although scientists have studied the effects of fructose in healthy people, no studies so far have included people with MASH, so it is not known if fructose might make the condition worse. To answer this question, the researchers will conduct a four-week randomised, double-blind study to compare the effects of fructose with another sugar called glucose in 36 people with MASH, 18 people with 'simple' MASLD, and 18 controls without liver disease. Participants will follow a low-sugar diet and, after 14 days on this diet, they will add either a glucose or fructose supplement for another 14 days. Participants will attend 3 study visits, where blood, urine, stool, and saliva samples will be taken. The main question is whether fructose causes more inflammation in people with MASH compared to those with MASLD, or people without liver disease. The researchers will also investigate how fructose affects liver fat content, the gut microbiota, and other processes relevant to MASLD/MASH.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07013916
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of fructose
Trials testing the same drug.
- NCT05717595 — BaRiatric Surgery AnD FRUctose Handeling In Obese subjecTs · NA · unknown
- NCT00686608 — Hypothalamic Functional Magnetic Resonance Imaging (fMRI) Response to Nutrients · Phase 2 · completed
Other recruiting trials for MASH - Metabolic Dysfunction-Associated Steatohepatitis
Currently open trials in the same condition.
- NCT07249788 — Resmiterom Efficacy & Safety in Patients With MASH · Phase 4 · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT07463287 — High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps · recruiting
Other Queen Mary University of London trials
Trials by the same sponsor.
- NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
- NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
- NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
- NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
- NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07013916 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07013916.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing